GlaxoSmithKline inked trial software firm Medable to a four-year deal to use its platform for decentralized clinical trials and to recruit more diverse trial patient populations.
GSK said it would use Medable’s platform across its portfolio of products. Financial terms of the deal weren’t disclosed.
Medable offers GSK a decentralized clinical trial platform that includes digital capabilities such as eConsent, TeleVisit, eCOA and the flexibility to deploy modern, patient-centered clinical trials.
“GSK has been a leader in innovative science for decades and is taking yet another transformational step forward by leveraging a modern, patient-centric model to conduct clinical trials with Medable,” Michelle Longmire, M.D., Medable’s chief executive, said in a statement.
Medable, which has used its platform for more than 300 decentralized and hybrid clinical trials spanning 60 countries, announced in July that it was working with medical device developer Withings Health Solutions.
Earlier this year, Palo Alto, California-based Medable signed on with CVS Health for clinical trials at select MinuteClinics. The same day as the CVS announcement, Medable acquired Leo Innovation’s Denmark-based Omhu, which develops skin-tracking apps that let patients submit photographs for assessment by dermatologists.